185 related articles for article (PubMed ID: 34282593)
1. Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature.
Sari R; Altinoz MA; Ozlu EBK; Sav A; Danyeli AE; Baskan O; Er O; Elmaci I
Horm Metab Res; 2021 Jul; 53(7):413-424. PubMed ID: 34282593
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
3. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Whitelaw BC; Dworakowska D; Thomas NW; Barazi S; Riordan-Eva P; King AP; Hampton T; Landau DB; Lipscomb D; Buchanan CR; Gilbert JA; Aylwin SJ
Clin Endocrinol (Oxf); 2012 Jun; 76(6):877-86. PubMed ID: 22372583
[TBL] [Abstract][Full Text] [Related]
5. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
6. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
7. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy in aggressive or dopamine agonists resistant prolactinomas; is it still worthwhile?
Niculescu DA; Gheorghiu ML; Poiana C
Eur J Endocrinol; 2023 Apr; 188(4):R88-R97. PubMed ID: 36975104
[TBL] [Abstract][Full Text] [Related]
9. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 and Clinical Correlations in Patients with Resistant Prolactinomas.
Lu C; Liu Y; Lu Z; Huan C
Ann Clin Lab Sci; 2020 Mar; 50(2):199-204. PubMed ID: 32366557
[TBL] [Abstract][Full Text] [Related]
11. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
12. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of difficult to treat macroprolactinomas.
Sahakian N; Castinetti F; Dufour H; Graillon T; Romanet P; Barlier A; Brue T; Cuny T
Expert Rev Endocrinol Metab; 2019 May; 14(3):179-192. PubMed ID: 30913932
[TBL] [Abstract][Full Text] [Related]
14. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
15. Aggressive and Malignant Prolactinomas.
Olarescu NC; Perez-Rivas LG; Gatto F; Cuny T; Tichomirowa MA; Tamagno G; Gahete MD;
Neuroendocrinology; 2019; 109(1):57-69. PubMed ID: 30677777
[TBL] [Abstract][Full Text] [Related]
16. Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors.
Raverot G; Vasiljevic A; Jouanneau E; Lasolle H
Eur J Endocrinol; 2019 Aug; 181(2):C1-C3. PubMed ID: 31167164
[TBL] [Abstract][Full Text] [Related]
17. Therapy of aggressive pituitary tumors.
Colao A; Grasso LF; Pivonello R; Lombardi G
Expert Opin Pharmacother; 2011 Jul; 12(10):1561-70. PubMed ID: 21434849
[TBL] [Abstract][Full Text] [Related]
18. Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Souteiro P; Karavitaki N
Pituitary; 2020 Feb; 23(1):27-37. PubMed ID: 31522358
[TBL] [Abstract][Full Text] [Related]
19. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
20. The treatment of aggressive prolactinomas with everolimus.
Lin AL; Geer EB; Lala N; Page-Wilson G; Magge R; Young RJ; Tabar V
Pituitary; 2023 Aug; 26(4):474-481. PubMed ID: 37428396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
